Discover
CTKB
Cytek Biosciences, Inc.
4.58
2 x 3.29
2 x 5.68
bid
ask
+
0.15
3.39%
2 @ 05:45 AM
4.84 +0.26 (5.68%)
| Ytd | -9.31% | |
| 1y | 31.61% |
4.42
day range
4.61
3.09
52 week range
6.18
| Open | 4.45 | Prev Close | 4.43 | Low | 4.42 | High | 4.61 | Mkt Cap | 591.47M |
| Vol | 1.17M | Avg Vol | 1.32M | EPS | -0.58 | P/E | N/A | Forward P/E | 107.67 |
| Beta | 1.32 | Short Ratio | 4.50 | Inst. Own | 59.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.19 | 200-d Avg | 4.49 | 1yr Est | 8.40 |
| Income Statement | |||
| Total Revenue | 44.14M | ||
| Revenues (USD) | 44.14M | ||
| Cost of Revenue | 22.88M | ||
| Gross Profit | 21.25M | ||
| Operating Expenses | 39.72M | ||
| Research and Development Expense | 9.60M | ||
| Selling, General and Administrative Expense | 30.11M | ||
| Operating Income | -18.46M | ||
| Interest Expense | 262.00K | ||
| Income Tax Expense | 1.49M | ||
| Net Income | -18.87M | ||
| Net Income Common Stock | -18.87M | ||
| Net Income Common Stock (USD) | -18.87M | ||
| Consolidated Income | -18.87M | ||
| Earnings per Basic Share | -0.15 | ||
| Earnings per Basic Share (USD) | -0.15 | ||
| Earnings per Diluted Share | -0.15 | ||
| Earning Before Interest & Taxes (EBIT) | -17.11M | ||
| Earning Before Interest & Taxes (USD) | -17.11M | ||
| Weighted Average Shares | 128.70M | ||
| Weighted Average Shares Diluted | 128.70M | ||
| Balance Sheet | |||
| Cash and Equivalents | 65.67M | ||
| Cash and Equivalents (USD) | 65.67M | ||
| Investments | 196.56M | ||
| Investments Current | 196.56M | ||
| Trade and Non-Trade Receivables | 51.90M | ||
| Current Assets | 379.30M | ||
| Property, Plant & Equipment Net | 31.11M | ||
| Total Assets | 449.11M | ||
| Total Debt | 13.83M | ||
| Current Liabilities | 80.94M | ||
| Debt Non-Current | 13.83M | ||
| Total Liabilities | 121.47M | ||
| Accumulated Retained Earnings (Deficit) | -120.60M | ||
| Accumulated Other Comprehensive Income | 2.37M | ||
| Shareholders Equity | 327.64M | ||
| Shareholders Equity (USD) | 327.64M | ||
| Assets Non-Current | 69.81M | ||
| Total Debt (USD) | 13.83M | ||
| Deferred Revenue | 47.70M | ||
| Goodwill and Intangible Assets | 32.39M | ||
| Inventory | 49.79M | ||
| Liabilities Non-Current | 40.53M | ||
| Trade and Non-Trade Payables | 6.74M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.81M | ||
| Net Cash Flow from Financing | 3.98M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -25.19M | ||
| Capital Expenditure | -2.16M | ||
| Issuance (Purchase) of Equity Shares | 21.00K | ||
| Issuance (Repayment) of Debt Securities | 4.20M | ||
| Net Cash Flow from Investing | -27.08M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -24.88M | ||
| Net Cash Flow from Operations | -2.74M | ||
| Effect of Exchange Rate Changes on Cash | 646.00K | ||
| Share Based Compensation | 4.86M | ||